Efficacy of polyvalent bacteriophage P-27/HP to control multidrug resistant staphylococcus aureus associated with human infections

Current Microbiology

Volumn 62, Issue 1, 2011, Pages 255-260

  Gupta, Ragini ^a,b   Prasad, Yogendra ^b  

^a INDIAN VETERINARY RESEARCH INSTITUTE   (India)

^b M J P ROHILKHAND UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIINFECTIVE AGENT; CEFALEXIN; CHLORAMPHENICOL; CIPROFLOXACIN; GENTAMICIN; METICILLIN; NATURAL PRODUCT; PENICILLIN G; RIFAMPICIN; ROXITHROMYCIN; TETRACYCLINE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIOPHAGE; BACTERIOPHAGE P 27; BACTERIUM ISOLATE; BACTERIUM ISOLATION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SEWAGE; SPLEEN; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; BACTEREMIA; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INJECTIONS, SUBCUTANEOUS; MICE; MICROBIAL VIABILITY; SEWAGE; SPLEEN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS PHAGES;

BACTERIOPHAGE P27; MUS; STAPHYLOCOCCUS AUREUS;

EID: 79251525551     PISSN: 03438651     EISSN: 14320991     Source Type: Journal    
DOI: 10.1007/s00284-010-9699-x     Document Type: Article

References (20)

1. Adams MH (1959) Bacteriophages. Interscience, New York
2. S Anupurba MR Sen G Nath, et al. 2003 Prevalence of methicillin resistance Staphylococcus aureus in a tertiary referral hospital in eastern Uttar Pradesh Indian J Med Microbiol 21 1 49 51 1:STN:280:DC%2BD2svisFSrsw%3D%3D 17642975
3. R Capparelli M Parlato G Borriello, et al. 2007 Experimental phage therapy against Staphylococcus aureus in mice Antimicrob Agents Chemother 51 2765 2773 10.1128/AAC.01513-06 1:CAS:528:DC%2BD2sXoslOjtbo%3D 10.1128/AAC.01513-06 17517843 (Pubitemid 47206211)
4. AL Casey PA Lambert TSJ Elliott 2007 Staphylococci Int J Antimicrob Agents 29 3 S23 S32 10.1016/S0924-8579(07)72175-1 1:CAS:528:DC%2BD2sXptV2hsLY%3D 10.1016/S0924-8579(07)72175-1 17659209 (Pubitemid 47058921)
5. HF Chamber 2005 Community-associated MRSA-resistance and virulence converge New Engl J Med 352 1485 1487 10.1056/NEJMe058023 (Pubitemid 40471458)
6. Cowan ST, Steel KJ (1975) Manual for identification of medical bacteria. Cambridge University press, London
7. J El-Jakee AS Nagwa M Bakry, et al. 2008 Characteristics of Staphylococcus aureus strains isolated from human and animal sources Am Eurasian J Agric Environ Sci 4 2 221 229
8. Eisenstark A (1967) Bacteriophage techniques. In: Maramorsch K, Koprowski H (eds) Methods in virology 1. Academic press, New York, pp 449-524
9. A Gorski R Miedzybrodzki J Borysowski, et al. 2009 Bacteriophage therapy for the treatment of infections Curr Opin Investig Drugs 10 8 766 774 1:CAS:528:DC%2BC3cXnt1KhsLw%3D 19649921
10. JA Jernigan BM Farr 1993 Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis Ann Intern Med 119 304 311 1:STN:280:DyaK3szhvFWqsA%3D%3D 8328740
11. FD Lowy 2003 Antimicrobial resistance: the example of Staphylococcus aureus J Clin Invest 111 1265 1273 10.1172/JCI200318535 1:CAS:528: DC%2BD3sXjsFCku7s%3D 12727914 (Pubitemid 36554694)
12. S Matsuzaki M Yasuda H Nishikawa, et al. 2003 Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11 J Infect Dis 187 613 624 10.1086/374001 1:CAS:528:DC%2BD3sXit1yhtL4%3D 10.1086/374001 12599078 (Pubitemid 36250025)
13. Merabishvili M, Pirnay JP, Verbeken G et al (2009) Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 4(3):e4944. doi: 10.1371/journal.pone.0004944
14. National Committee for Clinical Laboratory Standards (2000) Performance standards for antimicrobial disk susceptibility tests: approved standard M2-A6, 7th edn. NCCLS, Wayne, PA
15. S O'Flaherty RP Ross W Meaney, et al. 2005 Potential of the polyvalent anti-Staphylococcus bacteriophage K for the control of antibiotic-resistant staphylococci from hospitals Appl Environ Microbiol 71 1836 1842 10.1128/AEM.71.4.1836-1842.2005 10.1128/AEM.71.4.1836-1842.2005 15812009 (Pubitemid 40546101)
16. S O'Flaherty RP Ross A Coffey 2009 Bacteriophage and their lysins for elimination of infectious bacteria FEMS Microbiol Rev 33 801 819 10.1111/j.1574-6976.2009.00176.x 10.1111/j.1574-6976.2009.00176.x 19416364
17. RF Service 2004 Orphan drugs of the future? Science 303 1798 10.1126/science.303.5665.1798 10.1126/science.303.5665.1798 15031491
18. A Sulakvelidze Z Alavidze JG Morris Jr 2001 Bacteriophage therapy Antimicrob Agents Chemother 45 649 659 10.1128/AAC.45.3.649-659.2001 1:CAS:528:DC%2BD3MXhsFWgt78%3D 10.1128/AAC.45.3.649-659.2001 11181338 (Pubitemid 32182003)
19. Synnott AJ, Kuang Y, Kurimoto M et al (2009) Isolation from sewage influent and characterization of novel Staphylococcus aureus bacteriophages with wide host ranges and potent lytic capabilities. Appl Environ Microbiol 4483-4490. doi: 10.1128/AEM.02641-08
20. RP Wenzel G Bearman MB Edmond 2007 Community-acquired methicillin-resistant Staphylococcus aureus (MRSA): new issues for infection control Int J Antimicrob Agents 30 210 212 10.1016/j.ijantimicag.2007.04.003 1:CAS:528:DC%2BD2sXosFKqs70%3D 10.1016/j.ijantimicag.2007.04.003 17566712 (Pubitemid 47135624)